Dara BioSciences stock falls after pricing public offering

Posted by David Bracken on May 30, 2014 

Dara BioSciences has priced the shares of its preferred stock offering at $1.11.

The company’s shares, which opened Friday at $1.60, were down more than 20 percent in early trading.

Dara expects its proceeds from the sale to total $11.3 million after deducting fees and expenses. The sale is expected to close by the middle of next week.

The company plans to use the proceeds from the sale to fund "commercial activities related to our product portfolio," and to finance the acquisition of other approved products, among other uses.

Dara is desperately in need of cash, and has been forced to reduce the size of its offering significantly. It earlier filed plans to raise as much as $32.5 million through a sale of stock and warrants.

The company reported earlier this month that it has only enough money to fund operations through the third quarter of this year. As of March 31, the Dara had $6.838 million in cash. The company raised $6 million in the first quarter through a sale of stock and warrants.

News & Observer is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Commenting FAQs | Terms of Service